文献速递心力衰竭与心肌病瓣膜病与结构性心脏病

COAPT试验:经导管二尖瓣修复治疗继发性二尖瓣反流临床应答的预测因素

Predictors of Clinical Response to Transcatheter Reduction of Secondary Mitral Regurgitation: The COAPT Trial.
PubMed 文献 · J Am Coll Cardiol · 2020-01-01

COAPT试验纳入614例心力衰竭合并重度继发性二尖瓣反流患者,随机接受MitraClip+GDMT或单纯GDMT。12个月时MitraClip组超级应答者27.2%、应答者19.0%、无应答者53.8%,GDMT组分别为10.2%、16.3%、73.5%(总体p<0.0001)。基线较低血清肌酐、较低KCCQ-OS评分及MitraClip治疗是临床应答的独立预测因素。

要点

  • MitraClip组12个月超级应答者比例高于GDMT组(27.2% vs 10.2%)。
  • 基线较低血清肌酐和较低KCCQ-OS评分预测更好的临床应答。
  • 30天时MR程度改善和右室收缩压降低与长期良好应答相关。

核心结论

  • 基线较低血清肌酐、较低KCCQ-OS评分及MitraClip治疗是COAPT试验中临床超级应答者的独立预测因素。
  • 30天时MR严重程度改善和右室收缩压降低与经导管二尖瓣修复后长期良好临床应答相关。

研究设计与样本

  • COAPT试验为随机对照试验,纳入614例接受最大耐受指南导向药物治疗(GDMT)仍有症状的心力衰竭合并重度继发性二尖瓣反流患者,随机分配至MitraClip+GDMT或单纯GDMT。
  • 超级应答者定义为12个月时存活且无HF住院、KCCQ-OS评分改善≥20分;应答者定义为存活且无HF住院、KCCQ-OS改善5至<20分;无应答者为死亡、HF住院或KCCQ-OS改善<5分。

主要发现

  • 614例入组患者中41例(6.7%)因缺失KCCQ-OS数据无法分类。
  • 12个月时MitraClip组超级应答者79例(27.2%)、应答者55例(19.0%)、无应答者156例(53.8%);GDMT组分别为29例(10.2%)、46例(16.3%)、208例(73.5%)(总体p<0.0001)。
  • 超级应答者和应答者30天时MR分级和估计右室收缩压改善程度更大,无应答者未改善。

关键数值与推荐

  • 超级应答:12个月存活、无HF住院且KCCQ-OS改善≥20分。
  • 应答:12个月存活、无HF住院且KCCQ-OS改善5至<20分。
  • 无应答:死亡、HF住院或KCCQ-OS改善<5分。

临床怎么用

  • 对心力衰竭合并重度继发性二尖瓣反流患者,基线血清肌酐较低和KCCQ-OS评分较低者接受MitraClip治疗后更可能获得显著临床应答。
  • 术后30天MR程度改善和右室收缩压降低可提示长期临床应答良好。

局限性

  • 41例(6.7%)患者因缺失KCCQ-OS数据无法分类。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Transcatheter mitral valve repair with the MitraClip results in marked clinical improvement in some but not all patients with secondary mitral regurgitation (MR) and heart failure (HF). OBJECTIVES: This study sought to evaluate the clinical predictors of a major response to treatment in the COAPT trial. METHODS: Patients with HF and severe MR who were symptomatic on maximally tolerated guideline-directed medical therapy (GDMT) were randomly assigned to MitraClip plus GDMT or GDMT alone. Super-responders were defined as those alive without HF hospitalization and with ≥20-point improvement in the Kansas City Cardiomyopathy Questionnaire overall summary (KCCQ-OS) score at 12 months. Responders were defined as those alive without HF hospitalization and with a 5 to <20-point KCCQ-OS improvement at 12 months. Nonresponders were those who either died, were hospitalized for HF, or had <5-point improvement in KCCQ-OS at 12 months. RESULTS: Among 614 enrolled patients, 41 (6.7%) had missing KCCQ-OS data and could not be classified. At 12 months, there were 79 super-responders (27.2%), 55 responders (19.0%), and 156 nonresponders (53.8%) in the MitraClip arm compared with 29 super-responders (10.2%), 46 responders (16.3%), and 208 nonresponders (73.5%) in the GDMT-alone arm (overall p < 0.0001). Independent baseline predictors of clinical responder status were lower serum creatinine and KCCQ-OS scores and treatment assignment to MitraClip. MR grade and estimated right ventricular systolic pressure at 30 days were improved to a greater degree in super-responders and responders but not in nonresponders. CONCLUSIONS: Baseline predictors of clinical super-responders in patients with HF and severe secondary MR in the COAPT trial were lower serum creatinine, KCCQ-OS score and MitraClip treatment. Improved MR severity and reduced right ventricular systolic pressure at 30 days are associated with a long-term favorable clinical response after transcatheter mitral valve repair. (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation [COAPT]; NCT01626079).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Grayburn PA, Sannino A, Cohen DJ, et al. Predictors of Clinical Response to Transcatheter Reduction of Secondary Mitral Regurgitation: The COAPT Trial. J Am Coll Cardiol. 2020. PMID: 32854834. doi:10.1016/j.jacc.2020.07.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。